The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    March 2020

  • Pages
    172

  • View Count
    1919

Example Insights

Fragment-based-Drug-Discovery-Market-Context Fragment-based-Drug-Discovery-Service-Providers Fragment-based-Drug-Discovery-Stakeholders
Fragment-based-Drug-Discovery-Distribution-by-location Fragment-based-Drug-Discovery-Competitiveness-analysis Fragment-based-Drug-Discovery-Partnerships-and-collaborations
Fragment-based-Drug-Discovery-Futuer-forecast Fragment-based-Drug-Discovery-Market-forecast  

 

Overview

Drug discovery and development is a complex and tedious process that requires a significant amount of resources and capital investment (~USD 2.6 billion). In fact, on an average, the journey from the establishment of initial proof-of-concept to commercial launch, is estimated to take around 10-12 years. However, only a small fraction of early stage therapeutic candidates are able to make it past preclinical testing, into clinical evaluation. Further, even fewer clinical stage candidates are eventually approved for commercialization. Given the growing complexity in drug discovery research, the overall expenditure on pharmaceutical / biotechnology R&D has steadily increased over time. Specifically, in 2019, R&D spending was estimated to be around USD 182 billion, with more than 16,000 drug molecules evaluated during the course of the whole year. The industry is presently under tremendous pressure to not only identify ways to mitigate the risks of failure of drug discovery programs, but also to meet the expectations / medical needs of a growing patient population.

Despite its many advantages, high-throughput screening (HTS) is an expensive process and pharmacological leads generated via this process have been associated with high attrition rates during preclinical development. In addition, this approach is also limited in terms of the number of compounds that can be developed and stored in compound libraries. Fragment-based drug discovery (FBDD), is a relatively new hit screening approach. which has been shown to offer a number of benefits, including a cost advantage and the potential to enable the generation of hits with improved physiochemical properties, over HTS. In this context, it is worth highlighting that three marketed drugs, namely Vemurafenib (ZELBORAF®), Venetoclax (VENCLEXTA®), and Erdafitinib (BALVERSA™), originated from fragment-based library screens. Nearly 40 candidates discovered via the FBDD approach are in clinical trials. In fact, currently, over 50% of discovery projects are estimated to be using the FBDD approach, which uses biophysical techniques such as X ray crystallography and nuclear magnetic resonance. Further, the availability of bespoke fragment collections designed against individual biological targets / target families is expected to facilitate the discovery of potent pharmaceutical leads against more challenging targets, such as protein-protein interactions and allosteric sites on enzymes.

Scope of the Report

The “Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of this approach over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed review of the overall landscape of  fragment-based drug discovery library and service providers along with the information on type of product (library and technology), type of service offered (fragment screening and fragment optimization), type of technique used (X-ray crystallography, nuclear magnetic resonance, surface plasmon resonance, and other screening techniques), other services offered (target identification / validation, hit identification, hit-to-lead / lead generation, lead optimization), and end user (industry, academia, and contract research organizations).
  • Elaborate profiles of the companies providing libraries and services for fragment-based drug discovery (shortlisted on the basis of the service portfolio and number of fragment screening techniques offered). Each profile features a brief overview of the company, its financial information (if available), fragment-based library and service portfolio, information on other drug discovery services, recent developments and an informed future outlook.
  • An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, mergers and acquisitions, product development and commercialization agreements, commercialization agreements, distribution and supply agreements, product integration agreements, service agreements, and other relevant types of deals.
  • A detailed analysis on acquisition targets, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2015, and offering a means for other industry stakeholders to identify potential acquisition targets.
  • An insightful competitiveness analysis of fragment-based drug discovery library and service providers, based on supplier power (based on the years of experience of service provider) and key specifications, such as type of product, number of screening techniques, and the number of deals signed between 2015-2020.
  • An analysis highlighting the cost saving potential associated with the use of fragment-based drug discovery approach.

One of the key objectives of the report was to estimate the existing market size and the future opportunity for fragment-based drug discovery library and services, over the next decade. Based on multiple parameters, such as annual number of drug discovery projects, outsourcing profile, and adoption of fragment-based drug discovery approach, we have provided informed estimates on the evolution of the market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] type of technique (X-ray crystallography, nuclear magnetic resonance, surface plasmon resonance and other screening techniques), [B] type of service (library screening, fragment screening and fragment optimization), [C] end user (industry, academia and contract research organizations), and [D] key geographical regions (US, Canada, Germany, France, Italy, Spain, rest of Europe, Japan, China, and India). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Jean-Yves Ortholand, Co-founder & Chief Executive Officer, Edelris
  • Björn Walse, Chief Executive Officer, SARomics Biostructures

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of the market for fragment-based drug discovery and its likely evolution in the short-mid-term and long term.

Chapter 3 provides an introduction to the process of drug discovery and development. In addition, the chapter focuses on the concept of fragment-based drug discovery, highlighting its key advantages and drawbacks. It also features a brief discussion on the opportunities and the likely future trends in this field. 

Chapter 4 provides a detailed overview of the current market landscape of fragment-based drug discovery, including information on library and service providers, type of product (library and technology), type of service offered (fragment screening and fragment optimization), type of technique used (X-ray crystallography, nuclear magnetic resonance, surface plasmon resonance, and other screening techniques), other services offered (target identification / validation, hit identification, hit-to-lead / lead generation and lead optimization) and end user (industry players and non-industry players).

Chapter 5 includes detailed profiles of the companies providing library and services for fragment-based drug discovery (shortlisted on the basis of the service portfolio and number of fragment screening techniques offered). Each profile features a brief overview of the company, its financial information (if available), fragment-based library and service portfolio, information on other drug discovery services, recent developments and an informed future outlook.

Chapter 6 features an elaborate analysis of the partnerships that have been inked among various stakeholders in this domain, during 2015-2020. It includes a brief description of partnership models (such as research and development agreements, mergers and acquisitions, product development and commercialization agreements, distribution and supply agreements, service alliances, and commercialization agreements) adopted by the stakeholders.

Chapter 7 provides a detailed acquisition target analysis, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2015, and offering a means for other industry stakeholders to identify potential acquisition targets.

Chapter 8 provides an insightful competitiveness analysis of fragment-based drug discovery library and service providers, featuring a two-dimensional scatter plot representation. It highlights the key players in this domain, taking into consideration the supplier power (based on the year of establishment of service provider) and key specifications, such as number of fragment libraries and number of screening techniques.

Chapter 9 provides an analysis highlighting the cost saving potential associated with the use of fragment-based drug discovery approach.

Chapter 10 features an elaborate market forecast analysis, highlighting the likely growth of fragment-based drug discovery market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis [A] type of technique (X-ray crystallography, nuclear magnetic resonance, surface plasmon resonance and other screening techniques), [B] type of service (library screening, fragment screening and fragment optimization), [C] end user (industry players and non-industry players), and [D] key geographical regions (US, Canada, UK, Germany, France, Italy, Spain, rest of Europe, China, Japan, India, and rest of Asia-Pacific / rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

Chapter 11 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented a brief overview of the companies and details of our conversations held with Jean-Yves Ortholand (Co-founder & Chief Executive Officer, Edelris) and Björn Walse (Chief Executive Officer, SARomics Biostructures).

Chapter 12 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the fragment-based drug discovery industry. 

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 14 is an appendix, which contains a list of companies and organizations mentioned in this report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Drug Development

3.3. Drug Discovery Process
3.3.1. Target Identification
3.3.2. Target Validation
3.3.3. Hit Generation
3.3.4. Hit-to-Lead
3.3.5. Lead Optimization

3.4. High-Throughput Screening (HTS) and its Limitations

3.5. Fragment-based Drug Discovery (FBDD)
3.5.1. FBDD Strategies
3.5.2. Screening Techniques Used in FBDD

3.6. Challenges Related to FBDD
3.7. Future Perspectives

4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Fragment-based Drug Discovery: List of Library and Service Providers
4.2.1. Analysis by Year of Establishment of Company
4.2.2. Analysis by Company Size and Geographical Location
4.2.3. Leading Library and Service Providers: Analysis by Number of Products
4.2.4. Analysis by Geography
4.2.5. Analysis by Type of Service Offered
4.2.6. Analysis by Type of Technique Used
4.2.7. Analysis by Other Services Offered
4.2.8. Analysis by End User

4.3. Fragment-based Drug Discovery: List of Libraries and Technologies
4.3.1. Analysis by Type of Product

5. COMPANY PROFILES: FRAGMENT-BASED DRUG DISCOVERY LIBRARY AND SERVICE PROVIDERS
5.1. Chapter Overview

5.2. 2bind
5.2.1. Recent Developments and Future Outlook

5.3. Charles River Laboratories
5.3.1. Recent Developments and Future Outlook

5.4. ChemAxon
5.4.1. Recent Developments and Future Outlook

5.5. ComInnex
5.5.1. Recent Developments and Future Outlook

5.6. Creative Biolabs
5.6.1. Recent Developments and Future Outlook

5.7. Creative Biostructure

5.8. CRELUX
5.8.1. Recent Developments and Future Outlook

5.9. Domainex
5.9.1. Recent Developments and Future Outlook

5.10. Evotec
5.10.1. Recent Developments and Future Outlook

5.11. Red Glead Discovery

5.12. SARomics Biostructures

5.13. Shanghai ChemPartner
5.13.1. Recent Developments and Future Outlook

5.14. Sygnature Discovery
5.14.1. Recent Developments and Future Outlook

5.15. Vernalis Research
5.15.1. Recent Developments and Future Outlook

6. PARTNERSHIPS AND COLLABORATIONS
6.1. Chapter Overview
6.2. Partnership Models

6.3. Fragment-based Drug Discovery Services Market: List of Partnerships and Collaborations
6.3.1. Analysis by Year of Partnership
6.3.2. Analysis by Type of Partnership
6.3.3. Analysis by Year of Partnership and Type of Partner
6.3.4. Most Active Players: Analysis by Number of Partnerships
6.3.5. Regional Analysis
6.3.6. Intercontinental and Intracontinental Agreements

7. KEY ACQUISITION TARGETS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Scoring Criteria and Key Assumptions
7.4. Potential Strategic Acquisition Targets in North America
7.5. Potential Strategic Acquisition Targets in Europe
7.6. Potential Strategic Acquisition Targets in Asia-Pacific
7.7. Concluding Remarks

8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Methodology
8.3. Key Parameters
8.4. Competitiveness Analysis: Fragment-based Drug Discovery Library and Service Providers
8.4.1. Fragment-based Drug Discovery Library and Service Providers based in North America
8.4.2. Fragment-based Drug Discovery Library and Service Providers based in Europe
8.4.3. Fragment-based Drug Discovery Library and Service Providers based in Asia-Pacific

9. COST SAVING ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Parameters
9.3. Methodology
9.4. Overall Cost Saving Potential Associated with FBDD, 2020-2030
9.5. Concluding Remarks

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Forecast Methodology
10.3. Global Fragment-based Drug Discovery Market, 2020-2030
10.4. Global Fragment-based Drug Discovery Market: Distribution by Type of Technique, 2020 and 2030
10.4.1. Fragment-based Drug Discovery Market for X-ray Crystallography, 2020-2030
10.4.2. Fragment-based Drug Discovery Market for Nuclear Magnetic Resonance, 2020-2030
10.4.3. Fragment-based Drug Discovery Market for Surface Plasmon Resonance, 2020-2030
10.4.4. Fragment-based Drug Discovery Market for Other Screening Techniques, 2020-2030

10.5. Global Fragment-based Drug Discovery Market: Distribution by Type of Service, 2020 and 2030
10.5.1. Fragment-based Drug Discovery Market for Library Screening, 2020-2030
10.5.2. Fragment-based Drug Discovery Market for Fragment Screening, 2020-2030
10.5.3. Fragment-based Drug Discovery Market for Fragment Optimization, 2020-2030

10.6. Global Fragment-based Drug Discovery Market: Distribution by End User, 2020 and 2030
10.6.1. Fragment-based Drug Discovery Market for Industry Players, 2020-2030
10.6.2. Fragment-based Drug Discovery Market for Non-industry Players, 2020-2030

10.7. Global Fragment-based Drug Discovery Market: Distribution by Geography, 2020 and 2030
10.7.1. Fragment-based Drug Discovery Market in the US, 2020-2030
10.7.2. Fragment-based Drug Discovery Market in Canada, 2020-2030
10.7.3. Fragment-based Drug Discovery Market in the UK, 2020-2030
10.7.4. Fragment-based Drug Discovery Market in France, 2020-2030
10.7.5. Fragment-based Drug Discovery Market in Germany, 2020-2030
10.7.6. Fragment-based Drug Discovery Market in Spain, 2020-2030
10.7.7. Fragment-based Drug Discovery Market in Italy, 2020-2030
10.7.8. Fragment-based Drug Discovery Market in Rest of Europe, 2020-2030
10.7.9. Fragment-based Drug Discovery Market in China, 2020-2030
10.7.10. Fragment-based Drug Discovery Market in Japan, 2020-2030
10.7.11. Fragment-based Drug Discovery Market in India, 2020-2030
10.7.12. Fragment-based Drug Discovery Market in Rest of Asia-Pacific and Rest of the World, 2020-2030

11. EXECUTIVE INSIGHTS
11.1. Chapter Overview

11.2. Edelris
11.2.1. Company Snapshot
11.2.2. Interview Transcript: Jean-Yves Ortholand, Co-founder & Chief Executive Officer

11.3. SARomics Biostructures
11.3.1. Company Snapshot
11.3.2. Interview Transcript: Björn Walse, Chief Executive Officer

12. CONCLUDING REMARKS

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Drug Discovery and Development Timeline
Figure 3.2 Steps Involved in Drug Discovery Process
Figure 3.3 Fragment-based Drug Discovery Process: Fragment to Lead Optimization
Figure 3.4 Strategies in FBDD
Figure 3.5 Computational Fragment-based Drug Design
Figure 3.6 Screening Techniques Used for FBDD
Figure 4.1 Fragment-based Drug Discovery Library and Service Providers: Distribution by Year of Establishment
Figure 4.2 Fragment-based Drug Discovery Library and Service Providers: Distribution by Company Size and Geographical Location
Figure 4.3 Leading Library and Service Providers: Distribution by Number of Products
Figure 4.4 World Map Representation: Distribution by Geography
Figure 4.5 Fragment-based Drug Discovery Library and Service Providers: Distribution by Type of Technique Used
Figure 4.6 Fragment-based Drug Discovery Library and Service Providers: Distribution by Other Services Offered
Figure 4.7 Fragment-based Drug Discovery Library and Service Providers: Distribution by End User
Figure 4.8 Fragment-based Drug Discovery Library and Service Providers: Distribution by Type of Product
Figure 4.9 Fragment-based Drug Discovery Library and Service Providers: Distribution by Library Size
Figure 6.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2020 (till January)
Figure 6.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 6.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership (2015-2020)
Figure 6.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 6.5 Most Active Players: Distribution by Number of Partnerships
Figure 6.6 Partnerships and Collaborations: Regional Distribution
Figure 6.7 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 7.1 Likely Acquisition Targets: Geographical Distribution
Figure 8.1 Competitiveness Analysis: Fragment-based Drug Discovery Library Providers based in North America
Figure 8.2 Competitiveness Analysis: Fragment-based Drug Discovery Screening Service Providers based in North America
Figure 8.3 Competitiveness Analysis: Fragment-based Drug Discovery Library Providers based in Europe
Figure 8.4 Competitiveness Analysis: Fragment-based Drug Discovery Screening Service Providers based in Europe
Figure 8.5 Competitiveness Analysis: Fragment-based Drug Discovery Library Providers based in Asia-Pacific
Figure 8.6 Competitiveness Analysis: Fragment-based Drug Discovery Screening Service Providers based in Asia-Pacific
Figure 9.1 Approval Trend for Small Molecules: Historical Data (2005-2019)
Figure 9.2 Overall Cost Saving Potential of FBDD: Growth Scenarios
Figure 9.3 Overall Cost Saving Potential of Fragment-based Drug Discovery, 2020-2030 (USD Billion)
Figure 10.1 Global Fragment-based Drug Discovery Market, 2020-2030 (USD Million)
Figure 10.2 Global Fragment-based Drug Discovery Market: Distribution by Type of Technique, 2020 and 2030 (USD Million)
Figure 10.3 Fragment-based Drug Discovery Market for X-ray Crystallography, 2020-2030 (USD Million)
Figure 10.4 Fragment-based Drug Discovery Market for Nuclear Magnetic Resonance, 2020-2030 (USD Million)
Figure 10.5 Fragment-based Drug Discovery Market for Surface Plasmon Resonance, 2020-2030 (USD Million)
Figure 10.6 Fragment-based Drug Discovery Market for Other Screening Techniques, 2020-2030 (USD Million)
Figure 10.7 Global Fragment-based Drug Discovery Market: Distribution by Type of Service, 2020 and 2030 (USD Million)
Figure 10.8 Fragment-based Drug Discovery Market for Library Screening, 2020-2030 (USD Million)
Figure 10.9 Fragment-based Drug Discovery Market for Fragment Screening, 2020-2030 (USD Million)
Figure 10.10 Fragment-based Drug Discovery Market for Fragment Optimization, 2020-2030 (USD Million)
Figure 10.11 Global Fragment-based Drug Discovery Market: Distribution by End User, 2020 and 2030 (USD Million)
Figure 10.12 Fragment-based Drug Discovery Market for Industry Players, 2020-2030 (USD Million)
Figure 10.13 Fragment-based Drug Discovery Market for Non-industry Players, 2020-2030 (USD Million)
Figure 10.14 Global Fragment-based Drug Discovery Market: Distribution by Geography, 2020 and 2030 (USD Million)
Figure 10.15 Fragment-based Drug Discovery Market in the US, 2020-2030 (USD Million)
Figure 10.16 Fragment-based Drug Discovery Market in Canada, 2020-2030 (USD Million)
Figure 10.17 Fragment-based Drug Discovery Market in the UK, 2020-2030 (USD Million)
Figure 10.18 Fragment-based Drug Discovery Market in France, 2020-2030 (USD Million)
Figure 10.19 Fragment-based Drug Discovery Market in Germany, 2020-2030 (USD Million)
Figure 10.20 Fragment-based Drug Discovery Market in Spain, 2020-2030 (USD Million)
Figure 10.21 Fragment-based Drug Discovery Market in Italy, 2020-2030 (USD Million)
Figure 10.22 Fragment-based Drug Discovery Market in Rest of Europe, 2020-2030 (USD Million)
Figure 10.23 Fragment-based Drug Discovery Market in China, 2020-2030 (USD Million)
Figure 10.24 Fragment-based Drug Discovery Market in Japan, 2020-2030 (USD Million)
Figure 10.25 Fragment-based Drug Discovery Market in India, 2020-2030 (USD Million)
Figure 10.26 Fragment-based Drug Discovery Market in Rest of Asia-Pacific and Rest of the World, 2020-2030 (USD Million)

List Of Tables

Table 4.1 Fragment-based Drug Discovery: List of Library and Service Providers
Table 4.2 Fragment-based Drug Discovery: List of Drug Developers and Other Non-Industry Players
Table 4.3 Fragment-based Drug Discovery Library and Service Providers: Type of Service Offered
Table 4.4 Fragment-based Drug Discovery Library and Service Providers: Type of Technique Used
Table 4.5 Fragment-based Drug Discovery Library and Service Providers: Other Services Offered
Table 4.6 Fragment-based Drug Discovery Library and Service Providers: End Users
Table 4.7 Fragment-based Drug Discovery: List of Libraries and Technologies
Table 5.1 Fragment-based Drug Discovery Library and Service Providers: List of Profiled Companies
Table 5.2 2bind: Company Snapshot
Table 5.3 2bind: Recent Developments and Future Outlook
Table 5.4 Charles River Laboratories: Company Snapshot
Table 5.5 Charles River Laboratories: Recent Developments and Future Outlook
Table 5.6 ChemAxon: Company Snapshot
Table 5.7 ChemAxon: Recent Developments and Future Outlook
Table 5.8 ComInnex: Company Snapshot
Table 5.9 ComInnex: Recent Developments and Future Outlook
Table 5.10 Creative Biolabs: Company Snapshot
Table 5.11 Creative Biolabs: Recent Developments and Future Outlook
Table 5.12 Creative Biostructure: Company Snapshot
Table 5.13 CRELUX: Company Snapshot
Table 5.14 CRELUX: Recent Developments and Future Outlook
Table 5.15 Domainex: Company Snapshot
Table 5.16 Domainex: Recent Developments and Future Outlook
Table 5.17 Evotec: Company Snapshot
Table 5.18 Evotec: Recent Developments and Future Outlook
Table 5.19 Red Glead Discovery: Company Snapshot
Table 5.20 SARomics Biostructures: Company Snapshot
Table 5.21 Shanghai ChemPartner: Company Snapshot
Table 5.22 Shanghai ChemPartner: Recent Developments and Future Outlook
Table 5.23 Sygnature Discovery: Company Snapshot
Table 5.24 Sygnature Discovery: Recent Developments and Future Outlook
Table 5.25 Vernalis Research: Company Snapshot
Table 5.26 Vernalis Research: Recent Developments and Future Outlook
Table 6.1 Fragment-based Drug Discovery Services Market: List of Partnerships and Collaborations
Table 7.1 North America: Likely Targets for Acquisition
Table 7.2 Europe: Likely Targets for Acquisition
Table 7.3 Asia-Pacific: Likely Targets for Acquisition
Table 9.1 Drug Discovery Steps: Key Parameters
Table 11.1 Edelris: Key Highlights
Table 11.2 SARomics Biostructures: Key Highlights
Table 12.1 Fragment-based Drug Discovery Library and Service Providers: Summary of the Competitive Insights
Table 13.1 Fragment-based Drug Discovery Library and Service Providers: Distribution by Year of Establishment
Table 13.2 Fragment-based Drug Discovery Library and Service Providers: Distribution by Company Size and Geographical Location
Table 13.3 Leading Library and Service Providers: Distribution by Number of Products
Table 13.4 Fragment-based Drug Discovery Library and Service Providers: Distribution by Type of Technique Used
Table 13.5 Fragment-based Drug Discovery Library and Service Providers: Distribution by Other Services Offered
Table 13.6 Fragment-based Drug Discovery Library and Service Providers: Distribution by End User
Table 13.7 Fragment-based Drug Discovery Library and Service Providers: Distribution by Type of Product
Table 13.8 Fragment-based Drug Discovery Library and Service Providers: Distribution by Library Size
Table 13.9 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2020 (till January)
Table 13.10 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.11 Partnerships and Collaborations: Distribution by Year and Type of Partnership (2015-2020)
Table 13.12 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 13.13 Most Active Players: Distribution by Number of Partnerships
Table 13.14 Partnerships and Collaborations: Regional Distribution
Table 13.15 Approval Trend for Small Molecules: Historical Data (2005-2019)
Table 13.16 Overall Cost Saving Potential of Fragment-based Drug Discovery, 2020-2030 (USD Billion)
Table 13.17 Global Fragment-based Drug Discovery Market, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.18 Global Fragment-based Drug Discovery Market: Distribution by Type of Technique, 2020 and 2030 (USD Million)
Table 13.19 Fragment-based Drug Discovery Market for X-ray Crystallography, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.20 Fragment-based Drug Discovery Market for Nuclear Magnetic Resonance, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.21 Fragment-based Drug Discovery Market for Surface Plasmon Resonance, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.22 Fragment-based Drug Discovery Market for Other Screening Techniques, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.23 Global Fragment-based Drug Discovery Market: Distribution by Type of Service, 2020 and 2030 (USD Million)
Table 13.24 Fragment-based Drug Discovery Market for Library Screening, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.25 Fragment-based Drug Discovery Market for Fragment Screening, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.26 Fragment-based Drug Discovery Market for Fragment Optimization, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.27 Global Fragment-based Drug Discovery Market: Distribution by End User, 2020 and 2030 (USD Million)
Table 13.28 Fragment-based Drug Discovery Market for Industry Players, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.29 Fragment-based Drug Discovery Market for Non-industry Players, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.30 Global Fragment-based Drug Discovery Market: Distribution by Geography, 2020 and 2030 (USD Million)
Table 13.31 Fragment-based Drug Discovery Market in the US, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.32 Fragment-based Drug Discovery Market in Canada, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.33 Fragment-based Drug Discovery Market in the UK, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.34 Fragment-based Drug Discovery Market in France, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.35 Fragment-based Drug Discovery Market in Germany, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.36 Fragment-based Drug Discovery Market in Spain, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.37 Fragment-based Drug Discovery Market in Italy, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.38 Fragment-based Drug Discovery Market in Rest of Europe, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.39 Fragment-based Drug Discovery Market in China, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.40 Fragment-based Drug Discovery Market in Japan, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.41 Fragment-based Drug Discovery Market in India, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.42 Fragment-based Drug Discovery Market in Rest of Asia-Pacific and Rest of the World, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)

Listed Companies

  1. 2bind
  2. Accelero Biostructures
  3. Advanced Chemistry Development (ACD / Labs)
  4. Agilent Technologies
  5. Allesh Biosciences Labs
  6. Altaris Capital Partners
  7. Astex Pharmaceuticals
  8. AstraZeneca
  9. Aunova Medchem
  10. Aurora Fine Chemicals
  11. Axxam
  12. Basilea Pharmaceutica
  13. Beactica
  14. Bellvitge Biomedical Research Institute (IDIBELL)
  15. BioAscent
  16. BioBlocks
  17. BioPredict
  18. BioSolveIT
  19. BOC Sciences
  20. Boehringer Ingelheim
  21. Bruker
  22. C4X Discovery
  23. Cambridge Crystallographic Data Centre
  24. Cambridge MedChem Consulting
  25. Carna Biosciences
  26. Center for Drug Design and Discovery
  27. Centre for Chemical Biology and Therapeutics
  28. Charles River Laboratories
  29. CHDI Foundation
  30. ChemAxon
  31. ChemBridge
  32. ChemDiv
  33. Chemical Computing Group
  34. Collaborative Drug Discovery
  35. Collidion
  36. Columbia University
  37. ComInnex
  38. Conifer Point
  39. CreaGen
  40. Creative Biolabs
  41. Creative Biostructure
  42. CRELUX
  43. Creoptix
  44. Cresset
  45. CrystalsFirst
  46. Daiichi Sankyo
  47. Danaher
  48. Diamond Light Source
  49. Discover Drugs
  50. Domainex
  51. Dong-A ST
  52. DyNAbind
  53. Edelris
  54. Enamine
  55. Evotec
  56. Exscientia
  57. Fidelta
  58. Forge Therapeutics
  59. ForteBio
  60. GE Healthcare Life Sciences
  61. Gotham Therapeutics
  62. Helmholtz-Zentrum Berlin
  63. Heptares Therapeutics
  64. Heriot-Watt University
  65. Inte:Ligand
  66. IOTA Pharmaceuticals
  67. Jena Bioscience
  68. Jubilant Biosys
  69. Key Organics
  70. Keymodule
  71. Kinetic Discovery
  72. Kymab
  73. LeadInvent Technologies
  74. leadXpro
  75. LEO Pharma
  76. LG Chem
  77. Life Chemicals
  78. Ligand Pharmaceuticals
  79. Liverpool ChiroChem
  80. MAX IV Laboratory
  81. Max Planck Institute
  82. Maybridge
  83. Medicilon
  84. Medicines Discovery Catapult
  85. Merck
  86. Mestrelab Research
  87. MilliporeSigma
  88. Molecular Cornerstones
  89. Molecular Devices
  90. NMX Research and Solutions
  91. Northwestern University
  92. NovaData Solutions
  93. NovAliX
  94. o2h discovery
  95. OMass Therapeutics
  96. omicX
  97. OpenEye Scientific Software
  98. Optibrium
  99. Organochem
  100. Origenis
  101. OTAVAchemicals
  102. Otsuka Pharmaceutical
  103. PeptiDream
  104. Pfizer
  105. Pharmacelera
  106. Pharmaron
  107. PhoreMost
  108. Pierre Fabre
  109. Plex Pharmaceuticals
  110. Plexxikon
  111. PMI BioPharma Solutions
  112. Prestwick Chemical
  113. Profacgen
  114. Prosarix
  115. Proteros Biostructures
  116. Pyxis Discovery
  117. QuantumBio
  118. Reaction Biology
  119. Reaxense
  120. Red Glead Discovery
  121. RxCelerate
  122. SARomics Biostructures
  123. Selcia
  124. Selvita
  125. SensiQ
  126. Servier
  127. Shamrock Structures
  128. Shanghai ChemPartner
  129. Sharp Edge Labs
  130. Sierra Sensors
  131. SilcsBio
  132. Silicon Kinetics
  133. Sosei Heptares
  134. Spanish National Cancer Research Centre (CNIO)
  135. SpectralWorks
  136. SpiroChem
  137. Sprint Bioscience
  138. Structure based Design
  139. Sygnature Discovery
  140. SynphaTec Japon
  141. Taisho Pharmaceutical
  142. Takeda Pharmaceutical
  143. The Wistar Institute
  144. TimTec
  145. Universitat Autònoma de Barcelona
  146. University of Cambridge
  147. University of Nottingham
  148. Vernalis Research
  149. Viva Biotech
  150. Vlaams Instituut voor Biotechnologie
  151. WuXi AppTec
  152. Xtal BioStructures
  153. Zastra Innovations
  154. Zenobia Fragments
  155. ZoBio

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com